Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30682759 | 1.00 | CFD (0.42) | CFDCES2CES1 | |
| SCHEMBL30682599 | 1.00 | CFD (0.42) | CFDCES2CES1 | |
| SCHEMBL26951121 | 1.00 | CFD (0.42) | CFDCES2CES1 | |
| SCHEMBL26951120 | 1.00 | CFD (0.42) | CFDCES2CES1 | |
| SCHEMBL30682588 | 0.83 | IDO1 (0.40) | — | |
| SCHEMBL1727474 | 0.83 | IDO1 (0.40) | — | |
| SCHEMBL30682733 | 0.83 | IDO1 (0.40) | — | |
| SCHEMBL5205809 | 0.83 | IDO1 (0.40) | — | |
| SCHEMBL1728822 | 0.83 | IDO1 (0.40) | — | |
| SCHEMBL30682632 | 0.83 | IDO1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12338262-B2 | Modulators of TNF-alpha activity | FORWARD THERAPEUTICS, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20240279258-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | FORWARD THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| US-11987597-B2 | Modulators of TNF-α activity | FORWARD THERAPEUTICS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20240076306-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | FORWARD THERAPEUTICS, INC. | 2024-03-07 | — | — | US | disclosed |
| WO-2023240253-A2 | MODULATORS OF TNF-ALPHA ACTIVITY | FORWARD THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279258-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | TNF, TNFRSF1A, NFKBIA | CFD 3365/4885CES2 3419/4885CES1 598/4885 |
| US-11987597-B2 | Modulators of TNF-α activity | TNF, TNFRSF1A, NFKBIA | CFD 3527/4885CES2 3594/4885CES1 665/4885 |
| US-20240076306-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | TNF, TNFRSF1A, NFKBIA | CFD 3365/4885CES2 3419/4885CES1 598/4885 |
| US-12338262-B2 | Modulators of TNF-alpha activity | TNF, TNFRSF1A, NFKBIA | CFD 3365/4885CES2 3419/4885CES1 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.